Literature DB >> 33255979

Drug-Nutraceutical Co-Crystal and Salts for Making New and Improved Bi-Functional Analgesics.

Oli Abate Fulas1, André Laferrière1, Ghada Ayoub2, Dayaker Gandrath2, Cristina Mottillo2, Hatem M Titi2, Robin S Stein2, Tomislav Friščić2, Terence J Coderre1.   

Abstract

The discovery and development of effective analgesics is greatly lagging behind the steadily rising prevalence of chronic pain. Currently prescribed analgesics for chronic pain are lacking in efficacy mainly due to their narrowly-targeted mechanism of action. Driving neuronal hyperexcitability that underlies symptoms of chronic pain are multiple non-neuronal processes, among which are tissue hypoxia and oxidative stress. Here we demonstrate the design, synthesis, and activity of new multi-component bi-functional analgesic crystalline solids, co-crystals, and salts, based on pairing of vasodilatory anti-hypoxic drugs pentoxifylline, clonidine and linsidomine with antioxidant nutraceuticals protocatechuic acid, α-lipoic acid, and caffeic acid. After validation, chemical and structural characterization of these novel salts and co-crystals, topical formulations of the products were tested in a rat model of complex regional pain syndrome. Analgesic effects achieved with the salts and co-crystal exceeded the efficacy and/or potency of constituent compounds indicating that more effective, advanced analgesics can readily be developed by careful pairing of compounds that simultaneously target multiple neural and non-neural processes driving chronic pain.

Entities:  

Keywords:  CRPS; antioxidants; co-crystal; mechanochemistry; neuropathic pain; topical analgesics; vasodilators

Year:  2020        PMID: 33255979      PMCID: PMC7761172          DOI: 10.3390/pharmaceutics12121144

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  33 in total

Review 1.  Mechanism-based pain diagnosis: issues for analgesic drug development.

Authors:  C J Woolf; M B Max
Journal:  Anesthesiology       Date:  2001-07       Impact factor: 7.892

2.  Reversal of experimental diabetic neuropathy by VEGF gene transfer.

Authors:  P Schratzberger; D H Walter; K Rittig; F H Bahlmann; R Pola; C Curry; M Silver; J G Krainin; D H Weinberg; A H Ropper; J M Isner
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 3.  Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design.

Authors:  David J Berry; Jonathan W Steed
Journal:  Adv Drug Deliv Rev       Date:  2017-03-23       Impact factor: 15.470

Review 4.  Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development.

Authors:  Dipak Dilip Gadade; Sanjay Sudhakar Pekamwar
Journal:  Adv Pharm Bull       Date:  2016-12-22

Review 5.  The role of co-crystals in pharmaceutical design.

Authors:  Jonathan W Steed
Journal:  Trends Pharmacol Sci       Date:  2013-01-21       Impact factor: 14.819

6.  Clinical pharmacokinetics of molsidomine.

Authors:  B Rosenkranz; B R Winkelmann; M J Parnham
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

7.  Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth.

Authors:  Rudolf Kirchmair; Dirk H Walter; Masaaki Ii; Kilian Rittig; Anne B Tietz; Toshinori Murayama; Costanza Emanueli; Marcy Silver; Andrea Wecker; Carole Amant; Peter Schratzberger; Young-Sup Yoon; Alberto Weber; Eleftheria Panagiotou; Kenneth M Rosen; Ferdinand H Bahlmann; Lester S Adelman; David H Weinberg; Allan H Ropper; Jeffrey M Isner; Douglas W Losordo
Journal:  Circulation       Date:  2005-05-16       Impact factor: 29.690

8.  Peripheral nerve injury induces persistent vascular dysfunction and endoneurial hypoxia, contributing to the genesis of neuropathic pain.

Authors:  Tony K Y Lim; Xiang Q Shi; Julia M Johnson; Malena B Rone; Jack P Antel; Samuel David; Ji Zhang
Journal:  J Neurosci       Date:  2015-02-25       Impact factor: 6.167

9.  Complex regional pain syndrome: what's in a name?

Authors:  Terence J Coderre
Journal:  J Pain       Date:  2010-07-15       Impact factor: 5.820

10.  Drug-drug co-crystals.

Authors:  Bhupinder Singh Sekhon
Journal:  Daru       Date:  2012-10-04       Impact factor: 3.117

View more
  2 in total

1.  Oxidative stress is associated with characteristic features of the dysfunctional chronic pain phenotype.

Authors:  Stephen Bruehl; Ginger Milne; Jonathan Schildcrout; Yaping Shi; Sara Anderson; Andrew Shinar; Gregory Polkowski; Puneet Mishra; Frederic T Billings
Journal:  Pain       Date:  2022-04-01       Impact factor: 7.926

2.  A co-crystal berberine-ibuprofen improves obesity by inhibiting the protein kinases TBK1 and IKKɛ.

Authors:  Man Wang; Rong Xu; Xiaoli Liu; Ling Zhang; Siyan Qiu; Yuting Lu; Peng Zhang; Ming Yan; Jing Zhu
Journal:  Commun Biol       Date:  2022-08-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.